Deciphering and exploiting ferroptosis regulatory mechanism in cancer

DeciFERR aims to uncover mechanisms regulating ferroptosis to develop targeted therapies for challenging cancers like neuroblastoma by focusing on lipid oxidation pathways and key suppressors.

Subsidie
€ 1.985.356
2024

Projectdetails

Introduction

Ferroptosis is a cell death modality triggered by the accumulation of oxidised lipids, a process known as lipid oxidation, and is associated with a multitude of pathological conditions, including ageing, neurodegeneration, and cancer. On the flip side, recent studies demonstrated that targeting pathways contributing to the prevention or repair of oxidised lipids is a powerful strategy to eradicate therapeutically challenging entities, including neuroblastoma, a pediatric malignancy reported to be remarkably sensitive to ferroptosis.

Knowledge Gap

However, therapeutic breakthroughs targeting this pathway are elusive due to our incomplete understanding of the factors controlling this process. DeciFERR will address this critical knowledge gap and identify strategies to trigger ferroptosis. This will be accomplished by discovering and characterising novel mechanisms regulating the stability of key ferroptosis suppressors, thus providing opportunities to develop tailored strategies to target ferroptosis-sensitive entities.

Project Background

This project rests on our pioneering works identifying two major break systems operating against lipid peroxidation:

  1. Glutathione peroxidase 4 (GPX4)
  2. Ferroptosis suppressor protein 1 (FSP1)

Aim 1

In Aim 1, using a combination of novel cellular models and target-oriented phenotypic screens, we will characterise and target pathways involved in selenocysteine uptake, mobilisation, and recycling, which we found essential for the stability of selenoproteins, including GPX4.

Aim 2

In Aim 2, we will dissect metabolic and cellular states that determine the antioxidant capacity of membranes via FSP1-dependent mechanisms using a combination of cellular systems and functional genetic screens.

Conclusion

DeciFERR will lead to a comprehensive understanding of how ferroptosis is orchestrated and will expand the druggable inventory, providing innovative strategies that will be put to test and could ultimately pave the way for efficacious therapies against malignancies that still defy current treatments.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.985.356
Totale projectbegroting€ 1.985.356

Tijdlijn

Startdatum1-5-2024
Einddatum30-4-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Mitochondrial Strategies in Ferroptotic Cell Death

Mito-FerroQuest aims to explore mitochondrial communication and CoQ's role in preventing ferroptosis, potentially leading to new therapies for neurodegenerative disorders.

€ 1.500.000
ERC Starting...

Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy

This project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients.

€ 1.499.250
ERC Starting...

Understanding and targeting cancer persister cells

This project aims to develop tools for studying cancer persister cells using single-cell lineage tracing to enhance understanding and treatment of therapy-resistant tumors.

€ 1.728.750
ERC Consolid...

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

This project aims to reverse cancer cell plasticity in pediatric tumors using advanced genomic techniques to develop new therapeutic strategies for effective treatment.

€ 2.000.000
ERC Starting...

Targeting SWI/SNF-related chromatin remodelling defects in solid tumours

This project aims to uncover and exploit synthetic lethal vulnerabilities in SWI/SNF-deficient tumours to enhance anti-tumour immune responses and develop novel immuno-oncology therapies.

€ 1.499.887